Edition:
United Kingdom

Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

19.16USD
20 Apr 2018
Change (% chg)

$0.11 (+0.58%)
Prev Close
$19.05
Open
$18.97
Day's High
$19.24
Day's Low
$18.70
Volume
55,473
Avg. Vol
144,050
52-wk High
$30.70
52-wk Low
$11.89

Chart for

About

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform... (more)

Overall

Beta: 1.45
Market Cap(Mil.): $347.34
Shares Outstanding(Mil.): 22.69
Dividend: --
Yield (%): --

Financials

  CNCE.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -2.22 -- --
ROI: -45.62 1.58 14.38
ROE: -58.35 2.41 16.07

BRIEF-Concert Pharmaceuticals Inc Files For Mixed Shelf Offering Of Up To $250.0 Million - SEC Filing

* CONCERT PHARMACEUTICALS INC FILES FOR MIXED SHELF OFFERING OF UP TO $250.0 MILLION - SEC FILING Source text (http://bit.ly/2t6Qumw) Further company coverage: (Reuters.Brief@thomsonreuters.com)

01 Mar 2018

BRIEF-Concert Pharmaceuticals Reports Qtrly Loss Per Share $0.26

* CONCERT PHARMACEUTICALS REPORTS YEAR ENDED 2017 FINANCIAL RESULTS

01 Mar 2018

BRIEF-Concert Pharma Says Intends To Complete Evaluation And Advance CTP-692 Into Clinical Development By 2018 End

* CONCERT PHARMACEUTICALS INC SAYS INTENDS TO COMPLETE PRECLINICAL EVALUATION AND ADVANCE CTP-692 INTO CLINICAL DEVELOPMENT BY YEAR-END 2018 Source text for Eikon: Further company coverage:

28 Feb 2018

BRIEF-Concert Pharmaceuticals Initiates Enrollment In Second Cohort Of CTP-543 Trial

* CONCERT PHARMACEUTICALS ANNOUNCES INITIATION OF ENROLLMENT IN SECOND COHORT OF CTP-543 PHASE 2A TRIAL FOR ALOPECIA AREATA

12 Feb 2018

BRIEF-Concert Pharma Says FDA Granted Fast Track Designation To CTP-543

* FDA GRANTS FAST TRACK DESIGNATION TO CONCERT PHARMACEUTICALS’ CTP-543 FOR THE TREATMENT OF ALOPECIA AREATA

12 Jan 2018

BRIEF-Concert Pharmaceuticals Announces Patent Trial And Appeal Board Did Not Institute PGR Proceeding

* CONCERT PHARMACEUTICALS ANNOUNCES PATENT TRIAL AND APPEAL BOARD DID NOT INSTITUTE PGR PROCEEDING Source text for Eikon: Further company coverage:

12 Jan 2018

BRIEF-Concert Pharmaceuticals Announces Appointment Of Marc Becker As CFO

* CONCERT PHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF MARC BECKER AS CHIEF FINANCIAL OFFICER

18 Dec 2017

BRIEF-Concert Pharmaceuticals reports Q3 earnings per share $5.61

* Concert Pharmaceuticals reports third quarter 2017 financial results and provides company update

09 Nov 2017

BRIEF-Concert Pharmaceuticals announces completion of enrollment in First Cohort of CTP-543 phase 2a trial

* Concert Pharmaceuticals Inc announces completion of enrollment in First Cohort of CTP-543 phase 2a trial

06 Nov 2017

Earnings vs. Estimates